Skip to main content
Caplight Logo









Nanochon

Nanochon

Private
Washington D.C.Healthcare & Life Scienceshttps://nanochon.com/

Last Round

Seed

Jan 12, 2026

Est. Valuation

$4M

Total Funding Raised

$10.33M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Nanochon is a medical device company developing 3D-printed, synthetic implants designed to repair cartilage and encourage new tissue growth for patients with joint injuries.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, 3D Printing

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

orthopedic implantcartilage repairtissue engineering3D-printed implantregenerative medicineorthopedic scaffoldosteoarthritis treatmentbiotech implantmedical devicejoint repairmedtechhyaline cartilageorthobiologics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nanochon Comparables

Compare Nanochon with similar companies based on industry and business-model similarity.

Nanochon comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Regentis Biomaterials Ltd.
84%
Sparta Biomedical
83%
Askel Healthcare
83%

Nanochon Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJan 12, 2026
GrantOct 2, 2025
SeedMay 6, 2024
SeedOct 21, 2021
GrantJul 1, 2017

Key People

Founding team and executive leadership

Nathan Castro

Co-Founder And CTO

Founding Team

Matthew Scherer

Chief Financial Officer

Executive Team

Nanochon Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors increased 152% MoM.

  • Jan 12, 2026

    $4M round led by Cultivate(MD) and Ecphora Capital.

Recent news

Latest coverage and updates

  • receives_awardSep 2, 2026

    Nanochon receives award Breakthrough Device Designation.

  • is_developingAug 17, 2026

    Nanochon is developing Chondrograft on Aug 14th '26.

Nanochon Filings

Explore SEC and related filing metadata, where available.

Nanochon filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Nanochon's valuation, stock price, and market status.

Is Nanochon a public or private company?

Nanochon is a private company.

What is the current stock price of Nanochon?

Nanochon is a private company with no public stock price. No recent secondary market data is available.

How much is Nanochon worth (valuation)?

Valuation information for Nanochon is not publicly available.

Can I buy Nanochon stock?

Nanochon shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Nanochon's last funding round?

Nanochon's most recent funding round was Seed on January 12, 2026.

Who are the main investors in Nanochon?

Key investors in Nanochon include cultivate(MD).

Will Nanochon IPO soon?

No public IPO plans have been announced for Nanochon.

How can I track Nanochon secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nanochon's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersWashington D.C.
Employee Range12
Year Founded2013
Last FundingJan 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?